Recursion Pharmaceuticals, Inc. RXRX
We take great care to ensure that the data presented and summarized in this overview for RECURSION PHARMACEUTICALS, INC. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding RXRX
View all-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl32.8MShares$216 Million2.05% of portfolio
-
Baillie Gifford & CO25.2MShares$166 Million0.13% of portfolio
-
Vanguard Group Inc Valley Forge, PA24.3MShares$160 Million0.0% of portfolio
-
Black Rock Inc. New York, NY17.3MShares$114 Million0.0% of portfolio
-
Ra Capital Management, L.P. Boston, MA15.4MShares$101 Million1.41% of portfolio
-
State Street Corp Boston, MA12.9MShares$84.8 Million0.0% of portfolio
-
Kinnevik Ab (Publ) Stockholm, V711.9MShares$78.5 Million100.0% of portfolio
-
Sumitomo Mitsui Trust Holdings, Inc.9.77MShares$64.4 Million0.05% of portfolio
-
Nikko Asset Management Americas, Inc.9.69MShares$63.9 Million0.74% of portfolio
-
Mic Capital Management Uk LLP London, X08.45MShares$55.7 Million8.43% of portfolio
Latest Institutional Activity in RXRX
Top Purchases
Top Sells
About RXRX
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cavernous malformation; REC-2282 for the treatment of neurofibromatosis type 2; REC-4881 to treat familial adenomatous polyposis; and REC-3599, which is in Phase I clinical trial to treat GM2 gangliosidosis. Its preclinical stage product includes REC-3964 to treat Clostridium difficile colitis; REC-64917 for the treat of neural or systemic inflammation; REC-65029 to treat HRD-negative ovarian cancer; REC-648918 to enhance anti-tumor immune; REC-2029 for the treatment of wnt-mutant hepatocellular carcinoma; REC-14221 to treat solid and hematological malignancies; and REC-64151 for the treatment of immune checkpoint resistance in KRAS/STK11 mutant non-small cell lung cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Chromaderm, Inc.; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
Insider Transactions at RXRX
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 05
2024
|
Christopher Gibson Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
20,000
-2.64%
|
$140,000
$7.12 P/Share
|
|
Dec 05
2024
|
Christopher Gibson Chief Executive Officer |
BUY
Conversion of derivative security
|
Direct |
20,000
+2.58%
|
-
|
|
Dec 04
2024
|
Christopher Gibson Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
20,000
-2.64%
|
$140,000
$7.16 P/Share
|
|
Dec 04
2024
|
Christopher Gibson Chief Executive Officer |
BUY
Conversion of derivative security
|
Direct |
20,000
+2.58%
|
-
|
|
Nov 20
2024
|
Franziska Michor Director |
BUY
Grant, award, or other acquisition
|
Direct |
105,037
+31.26%
|
-
|
|
Nov 15
2024
|
Christopher Gibson Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
26,023
-3.41%
|
$156,138
$6.17 P/Share
|
|
Nov 15
2024
|
Tina Marriott Larson President and COO |
SELL
Payment of exercise price or tax liability
|
Direct |
14,286
-2.74%
|
$85,716
$6.17 P/Share
|
|
Nov 15
2024
|
Michael Secora Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
11,937
-0.8%
|
$71,622
$6.17 P/Share
|
|
Nov 15
2024
|
David J Mauro Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
4,187
-1.82%
|
$25,122
$6.17 P/Share
|
|
Nov 14
2024
|
Christopher Gibson Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
20,000
-2.56%
|
$140,000
$7.35 P/Share
|
|
Nov 14
2024
|
Christopher Gibson Chief Executive Officer |
BUY
Conversion of derivative security
|
Direct |
20,000
+2.49%
|
-
|
|
Nov 13
2024
|
Christopher Gibson Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
20,000
-2.56%
|
$140,000
$7.74 P/Share
|
|
Nov 13
2024
|
Christopher Gibson Chief Executive Officer |
BUY
Conversion of derivative security
|
Direct |
20,000
+2.49%
|
-
|
|
Nov 13
2024
|
Michael Secora Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
15,000
-0.99%
|
$105,000
$7.66 P/Share
|
|
Nov 13
2024
|
Michael Secora Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
39,375
+2.53%
|
$78,750
$2.22 P/Share
|
|
Nov 12
2024
|
Michael Secora Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
15,000
-1.01%
|
$105,000
$7.64 P/Share
|
|
Nov 12
2024
|
Michael Secora Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
39,375
+2.57%
|
$78,750
$2.22 P/Share
|
|
Nov 12
2024
|
Blake Borgeson Director |
SELL
Open market or private sale
|
Direct |
11,447
-0.16%
|
$80,129
$7.64 P/Share
|
|
Oct 29
2024
|
Blake Borgeson Director |
SELL
Open market or private sale
|
Direct |
11,447
-0.16%
|
$68,682
$6.72 P/Share
|
|
Oct 24
2024
|
Tina Marriott Larson President and COO |
SELL
Open market or private sale
|
Direct |
6,000
-1.14%
|
$36,000
$6.31 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 1.51M shares |
|---|---|
| Conversion of derivative security | 511K shares |
| Exercise of conversion of derivative security | 1.08M shares |
| Open market or private sale | 1.8M shares |
|---|---|
| Payment of exercise price or tax liability | 206K shares |
| Bona fide gift | 155K shares |